网络药理学和Shenfu Qiangxin的分子对接分析表明mTOR是治疗心力衰竭的潜在目标
Peilin Zou1,2, Jiajun Li3, Yucong Zhang1
1Department of Geriatrics, Tongji Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, 430030, China.
European journal of medical research
|March 14, 2024
概括
沈福清 (SFQX) 可以通过PI3K-Akt通路调节炎症和亡来治疗心力衰竭 (HF). 它的活性化合物准mTOR,这是心肌保护的关键蛋白质.
科学领域:
- 药理学 药理学是指药理学的学科.
- 系统生物学 系统生物学
- 传统中国医药 传统中国医药
背景情况:
- 心力衰竭 (HF) 是一个重要的全球死亡率挑战,复发率高.
- 由于其预后不佳,研究HF的新疗法机制至关重要.
- 传统中医药Shenfu Qiangxin (SFQX) 由于其心和利尿性质在治疗高血压中受到研究.
研究的目的:
- 阐明SFQX在治疗高血压时的潜在机制.
- 为了确定SFQX治疗HF的潜在药物点.
- 分析SFQX活性化合物及其蛋白标之间的相互作用.
主要方法:
- 使用疾病基因和TCM数据库建立了与HF相关的和SFQX向的基因组.
- 进行了基因功能和通路丰富分析.
- 构建了一个蛋白质-蛋白质相互作用 (PPI) 网络并进行分子对接.
主要成果:
- 鉴定了217个基因的基因组,揭示了SFQX在调节亡,炎症,氧化应激和缺氧方面的作用.
- 路径丰富分析突出了PI3K-Akt路径作为主要目标.
- 确定了mTOR作为PI3K-Akt通路中的关键枢纽基因,其中有6种活性SFQX化合物与其酶域结合.
结论:
- 网络药理学分析表明,SFQX干预HF治疗的PI3K-Akt通路.
- mTOR被确定为HF中心肌保护的关键药物标.
- 通过准mTOR和调节关键生物过程,SFQX展示了HF的潜在治疗机制.
相关概念视频
03:03mTOR Signaling and Cancer Progression
3.8K
The mammalian target of rapamycin or mTOR protein was discovered in 1994 due to its direct interaction with rapamycin. The protein gets its name from a yeast homolog called TOR. The mTOR protein complex in mammalian cells plays a major role in balancing anabolic processes such as the synthesis of proteins, lipids, and nucleotides and catabolic processes, such as autophagy in response to environmental cues, such as availability of nutrients and growth factors.
The mTOR pathway or the...
The mTOR pathway or the...
3.8K
01:22PI3K/mTOR/AKT Signaling Pathway
3.5K
The mammalian target of rapamycin (mTOR) is a serine/threonine kinase that regulates growth, proliferation, and cell survival in response to hormones, growth factors, or nutrient availability. This kinase exists in two structurally and functionally distinct forms: mTOR complex 1 (mTORC1) and mTOR complex 2 (mTORC2). The first form (mTORC1) is composed of a rapamycin-sensitive Raptor and proline-rich Akt substrate, PRAS40. In contrast, mTORC2 consists of a...
3.5K
01:26Heart Failure Drugs: Inhibitors of Renin-Angiotensin System
428
The activation of the sympathetic nervous system and the renin-angiotensin-aldosterone system (RAAS) contributes to cardiac remodeling, and inhibiting the RAAS is a pharmacological target in heart failure management. As a result, neurohumoral modulation is a crucial treatment principle for managing heart failure. This approach involves using medications like ACE inhibitors (ACEIs), angiotensin receptor blockers (ARBs), β-blockers, mineralocorticoid receptor antagonists (MRAs), and neutral...
428
01:26Heart Failure Drugs: Inotropic Agents
584
Positive inotropic agents are commonly used as the first line of treatment for heart failure. One such agent is digoxin, derived from the genus Digitalis, which has been known for centuries but effectively utilized since 1785. However, these cardiac glycosides can have potentially toxic effects due to their mechanism of action, which involves inhibiting Na+/K+-ATPase and increasing contractility. Digoxin is absorbed orally and distributed in various tissues, including the CNS. It has a long...
584
01:27Transducer Mechanism: Enzyme-Linked Receptors
2.5K
Enzyme-linked receptors are cell-surface receptors acting as an enzyme or associating with an enzyme intracellularly. They make excellent drug targets. Drugs can bind to the extracellular ligand-binding domain or directly affect their enzymatic domain and alter their activity.
Major types that are helpful drug targets include:
Major types that are helpful drug targets include:
2.5K
01:17Pathophysiology of Heart Failure
1.6K
Heart failure (HF) is a progressive syndrome involving ventricles that leads to inadequate cardiac output. It can be classified based on location and output or ejection fraction. Ejection fraction (EF) is an essential measurement in the diagnosis and surveillance of HF. Reduced EF corresponds to systolic heart failure (HFrEF). However, HF with preserved ejection fraction (HFpEF) is becoming increasingly prevalent. Also known as diastolic HF, this form of HF is related to aging. The...
1.6K